Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

This study tests whether adding a focused local treatment (such as radiation or ablation) to the small number of remaining disease sites after the targeted therapy osimertinib improves outcomes in patients with EGFR-mutated, stage IV non-small cell lung cancer. **You may be eligible if...** - You are 18 or older with confirmed non-small cell lung cancer and an EGFR exon 19 deletion or exon 21 L858R mutation - You have stage IV disease and are currently being treated with osimertinib (a targeted lung cancer drug) - After 12–24 weeks of osimertinib, your cancer has not progressed and you have 3 or fewer active disease sites that can receive local treatment - You have had at least one brain scan to check for brain involvement **You may NOT be eligible if...** - Your disease has progressed on osimertinib - You have more than 3 active disease sites - Your blood counts or organ function are below acceptable levels Talk to your doctor to see if this trial is right for you.